 | Up a level |
2017
Thelen, M., Lechner, A., Schloesser, H., Rothschild, S., Wennhold, K., Beutner, D. and von Bergwelt-Baildon, M. (2017). Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma (HNSCC). Oncol. Res. Treat., 40. S. 251 - 252. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Iltgen-Brebuda, J., Thelen, M., Wennhold, K., Rothschild, S., Becker, H., Schloesser, H., Shimabukuro-Vornhagen, A. and von Bergwelt-Baildon, M. (2017). Ruxolitinib modulates the antigen presenting function of activated B cells by interfering with metabolic pathways. Oncol. Res. Treat., 40. S. 262 - 263. BASEL: KARGER. ISSN 2296-5262
2016
Lechner, A., Schloesser, H., Rothschild, S., Thelen, M., Shimabukuro-Vornhagen, A., Beutner, D. and von Bergwelt-Baildon, M. (2016). Characterization of Tumor-associated B lymphocytes in head and neck squamous cell carcinoma. Oncol. Res. Treat., 39. S. 108 - 110. BASEL: KARGER. ISSN 2296-5262
Michels, S., Thurat, M., Schmalz, P., Pereira, E., Scheffler, M., Fischer, R., Sebastian, M., Abreu, D. R., Carcereny, E., Corral, J. J., Felip, E., Grohe, C., Insa, A., Thomas, M., Reck, M., Rothschild, S., Brandes, V, Nogova, L., Merkelbach-Bruse, S., Massuti, B., Buettner, R., Rosell, R. and Wolf, J. (2016). EUCROSS: A European phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - Preliminary results. Oncol. Res. Treat., 39. S. 209 - 211. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Iltgen, J., Wennhold, K., Marquez, M. Garcia, Rothschild, S., Schneider, B., Holtick, U., Thelen, M., Scheid, C., Becker, Hj, Schloesser, H., Reuter, S., Vornhagen, A. Shimabukuro and von Bergwelt-Baildon, M. (2016). THE JAK1/2 INHIBITOR RUXOLITINIB MODULATES ANTIGEN PRESENTING FUNCTIONS OF ACTIVATED PRIMARY B CELLS ON A METABOLIC LEVEL. Haematologica, 101. S. 462 - 463. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078